Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, has announced the 36-month results from its Phase 1/2a clinical study of RG6501 (OpRegen) for patients with geographic atrophy secondary to age-related macular degeneration. These results were presented at the Clinical Trials at the Summit 2025 by Dr. Christopher D. Riemann. The study demonstrated mean vision gains of +9 letters in patients who received extensive coverage of OpRegen cell therapy at the lesion site, with evidence of retinal structural improvement persisting for three years. This suggests anatomical and functional improvements following a single administration of the therapy. Additionally, the Phase 2a "GAlette study," which is evaluating the subretinal delivery of OpRegen cell therapy, is currently enrolling participants.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.